Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BP-013
- Development stage
- Preclinical
- Lead developer
- Brillian Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
BP-013 is a pediatric-focused reformulation of an existing cholesterol-lowering (lipid-lowering) medication developed by Brillian Pharma. Utilizing the company's proprietary "Unidose" drug delivery technology, BP-013 is designed as an oral solution or lyophilized powder for reconstitution to improve dosing accuracy and ease of administration in children. While the specific active pharmaceutical ingredient (API) is not publicly disclosed, the product aims to address the unmet need for child-friendly formats of standard lipid-lowering therapies. Brillian Pharma specializes in reformulating existing drugs into convenient single-dose formats rather than developing novel molecular entities.
Beyond the preview
Go deeper on BP-013.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BP-013.